RxDoctor Payments Data

Fredy El Sakr

Interventional Cardiology · Atlanta, GANPI 1780947390

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (57.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Medtronic at 50.7% of the total. Reporting peaked in 2024 at $15,074 and has fallen 60.0% since, to $6,028 in 2025.

$37,312in general payments, 2019–2025

Across 391 payments — averaging $95.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$19K
  • Edwards Lifesciences$5K
  • Abbott$4K
  • Boston Scientific$2K
  • Cardiovascular Systems Inc.$988
  • Cvrx, Inc.$622
  • plus $6K from 33 others
$1,259in research payments, 2019–2025

Across 2 payments — averaging $629.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$1K
  • Abiomed$59

What the payments were for

  • Consulting fees$360%
  • Travel & lodging$21,39557%
  • Food & beverage$15,65042%
  • Education$2321%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,312 in reported general payments places this provider in the 80th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$123,346
Medicare patients
412
Services billed
1,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$138,866
XareltoRivaroxaban15$22,791
Praluent PenAlirocumab16$11,678
Metoprolol Succinate126$1,878
Rosuvastatin Calcium122$1,773
Ezetimibe97$1,540
Atorvastatin Calcium194$1,437
Nifedipine ErNifedipine57$1,274
Losartan Potassium97$1,201
Carvedilol170$1,160
Potassium Chloride45$926
ClopidogrelClopidogrel Bisulfate67$782
Amlodipine Besylate95$465
Lisinopril65$450
Hydralazine Hcl38$389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$228$138,866131 claims
Johnson & JohnsonXarelto$250$22,79115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →